Zacks Investment Research
12 Dec 2025, 15:40 UTC · 40w ago
Verdict
Headline takes no side. We score ADMA +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Artivion (AORT) holds a Zacks Rank of #2 (Buy) and its current year EPS consensus estimate has increased 11.1% over the past three months.
More positive than 76% of claims this week
Adma Biologics (ADMA) holds a Zacks Rank of #2 (Buy) and its full-year earnings consensus estimate has increased 1.6% over the past 90 days.
Continue reading
5 related stories
Newsfile Corp
2h ago
PRNewsWire
5h ago
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 62% of claims this week
Adma Biologics has returned 18.8% year-to-date, outperforming both the broader Medical group (6.2% average) and its specific industry (18.8% average).
So whatHistorical price outperformance validates past momentum but has low impact on future price targets compared to forward-looking earnings revisions.
More positive than 43% of claims this week
Artivion has returned 59.1% year-to-date, significantly outperforming the Medical sector average.
More positive than 43% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), improving earnings estimates, and is outperforming its sector.
More positive than 84% of ticker scores this week
The stock has returned 59.1% year-to-date, has increasing EPS estimates, and a Zacks Rank of #2 (Buy).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−54.0%
Price is moving against the score
$9.37 vs $20.38 close before publication (Dec 11) · not market-adjusted
ADMA chart →
